• By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
In the last 2 hours
In the last 6 hours
FDA Roundup: July 23, 2024 U.S. Food and Drug Administration (Press Release)20:55 23-Jul-24
In the last 7 days
Monoclonal Antibody Risankizumab for Ulcerative Colitis Journal of American Medical Associations16:53 22-Jul-24
Risankizumab for Ulcerative Colitis Journal of American Medical Associations16:53 22-Jul-24
A Cellular Atlas of Gut Inflammation The Scientist15:06 22-Jul-24
How to Optimise Your Gut Health Thrive Global14:16 22-Jul-24
What you need to know about inflammatory bowel disease Knowridge Science Report11:17 19-Jul-24
by Guido Corradi Psyche11:04 18-Jul-24
Dr. Karlee Ausk Joins Washington Gastroenterology in Bellevue GlobeNewswire (Press Release)15:37 17-Jul-24
In the last month
Belonging while battling bowel disease The Tribune, California09:32 15-Jul-24
Treatments and prevention strategies for Crohn’s disease Knowridge Science Report11:20 14-Jul-24
Living With Colicky Pain Very Well Health17:51 12-Jul-24
PharmassêtX gains FDA orphan drug status for IBD drug Pharmaceutical Technology10:21 11-Jul-24
What IBD Means for My Dating Life Cosmopolitan US20:53 10-Jul-24
Puberty From Start to Finish: What Happens? Very Well Health23:30 9-Jul-24
Lilly to Acquire Morphic FinSMEs08:31 9-Jul-24
Lilly To Bolster IBD Pipeline With $3.2bn Morphic Bid Scrip Pharma Intelligence21:57 8-Jul-24
Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition Pharmaceutical Technology21:41 8-Jul-24
Eli Lilly Buys Morphic for $3.2B Investopedia15:07 8-Jul-24
Lilly agrees $3.2b IBD acquisition European Pharmaceutical Review14:01 8-Jul-24
Eli Lilly to buy bowel biopharma company Morphic Manufacturing Chemist12:30 8-Jul-24
view more headlines
24 Jul 11:32

About our Inflammatory Bowel Disease news

Latest news on inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis - symptoms, causes, treatments, research, and patient stories.

IBD affects over 10 million people worldwide. It is characterized by chronic inflammation of the gastrointestinal tract, leading to symptoms like abdominal pain, diarrhea, weight loss, and fatigue. Crohn's disease and ulcerative colitis are the two main types of IBD.

In a breakthrough discovery reported in Nature in June 2024, UK scientists identified a genetic weak spot present in 95% of IBD patients that allows certain immune cells to trigger excessive gut inflammation. Drugs targeting this pathway showed promise in lab experiments. Clinical trials could start within 5 years, offering hope for better IBD treatments.

Beyond medical advances, our IBD news feed covers practical matters like managing symptoms, patient support groups, and inspiring stories of people thriving despite IBD challenges. We highlight community events that raise IBD awareness and feature leading IBD charities like Crohn's & Colitis UK.

While the causes of IBD remain unclear, research suggests a combination of genetic predisposition, immune system malfunction, and environmental triggers. Notable risk factors include family history, smoking, and possibly diet. Over the past century, IBD prevalence has risen sharply, especially in industrialized nations, for reasons that continue to be investigated.

For comprehensive, up-to-date information on inflammatory bowel disease, our NewsNow IBD feed gathers the most relevant headlines from expert sources you can trust. It's an invaluable resource for everyone affected by or interested in IBD - patients, families, healthcare providers, researchers, and the wider public. With regular updates on the latest developments, you can rely on our IBD news feed to keep you fully informed.

Publication filters

Headline Density

Sorry, no headlines or news topics were found. Please try different keywords.